IV therapy and vein access devices are predicted to reach USD 28.7 billion by 2024. It is estimated that revenue will increase by 5.1% CAGR between 2024 and 2034. The IV therapy and vein access devices industry generated USD 27.3 billion in revenue in 2023. The market is projected to reach USD 47.3 billion by 2034.
The market is expected to be driven by an increase in the number of ambulatory clinics and specialized clinics over the forecast period. Increasing healthcare expenditures and increasing awareness of healthcare tactics have contributed to the rise in healthcare costs. Incidences of persistent illnesses are on the rise, and the number of surgeries is increasing globally.
Growing approvals of intravenous (IV) drugs and technological advances are expected to pressure the intravenous (IV) treatment and vein access market during the forecast period.
IV therapy recharges cells and improves mental clarity by providing fluids, nutrients, and vitamins that generate power. An IV treatment can immediately boost energy levels, leaving the individual feeling rejuvenated. Upon receiving IV therapy for persistent fatigue, patients report feeling more energized.
IV Drip therapy for strength replenishes the body's depleted energy stores and stimulates the growth of electricity. A traumatic lifestyle or nutritional deficiencies can cause fatigue, which can be treated with IV therapy. The treatment increases power levels by delivering essential vitamins, amino acids, and antioxidants to the body immediately.
IV Therapy and Vein Access Devices Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 27.3 billion |
| Estimated Size, 2024 | USD 28.7 billion |
| Projected Size, 2034 | USD 47.3 billion |
| Value-based CAGR (2024 to 2034) | 5.1% |
IV nutrition remedy, combined with chemotherapy, is beneficial for patients with cancer. Even though it no longer remedies cancer, it may help patients who are undergoing cancer treatment feel better and less fatigued. IV remedy does not always have to take place in a medical setting.
To receive vitamins, minerals, antioxidants, and medications directly into the bloodstream, many health-conscious individuals use IV hydration therapy. Supplementing with essential nutrients can help boost the immune system, enhance well-being, and assist with weight loss alone.
With advanced functions such as dose error discount software programs, wireless connectivity, and barcode scanning included in these pumps, medication errors are reduced to a minimum. Affected person protection and care can be improved through routine modifications of waft prices and the detection of potential problems with these pumps.
The use of ultrasound-guided devices assists clinicians in locating and accessing veins, especially in difficult venous access patients. Compared to conventional blind insertions, this method improves first-attempt success rates and decreases complications.
With wearable IV pumps, patients can receive IV treatment while walking and ambulating. Compared to traditional IV poles, these pumps provide patients with greater mobility and independence, improving their quality of life. Long-term venous access can be provided by implantable ports, which are placed under the skin near the collarbone. Long-term IV therapies, including chemotherapy and antibiotics, benefit from their ease of use.
With these structures, clinics can monitor catheter features and patient vital signs in real time, allowing early headache detection and intervention. In addition to improving the security and dressing of major venous access devices, these devices reduce complications and improve patient outcomes.
By examining new dressing methods and securement strategies, these technologies can save you from venous access failure. An assessment of recent securement and dressing technology will be conducted to stop relevant venous admissions leading to device failures in these trials
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Based on several semi-annual periods from 2024 through 2034, the following table illustrates the expected CAGR for IV therapy and vein access devices. A 6% growth rate is projected for the first half of the decade (H1), followed by a 5.7% rate for the second half (H2).
| Particular | Value CAGR |
|---|---|
| H1 | 6% (2023 to 2033) |
| H2 | 5.7% (2023 to 2033) |
| H1 | 5.1% (2024 to 2034) |
| H2 | 4.6% (2024 to 2034) |
According to analysts, the annual CAGR for H1 from 2024 to 2034 is expected to be 5.1% in the first half and 4.6% in the second half.
Influencing Factors of the IV Therapy and Vein Access Devices Market
IV therapy allows fluids, medicines, and nutrients to reach the body faster via the bloodstream, bypassing the stomach. The use of this technology enables clinicians to administer fluids effectively to patients. Due to its versatility, it can be used to treat a wide range of medical conditions.
A vein access device, like a significant catheter or peripherally inserted relevant catheter (PICC), is good for patients undergoing chemotherapy and prolonged treatment. Besides minimizing pain and scarring in the arm veins, these gadgets eliminate the need to repeatedly insert needles in the veins.
PICCs and central catheters can reduce headaches, tissue damage, and infiltration compared to conventional IV lines. A central catheter permits the infusion of medicines or nutritional supplements without the complications associated with an IV. Several vein access gadgets, such as ports and PICCs, are designed to be used over a long period of time.
Infusion ports, especially, only require positioning once and require minimal maintenance between infusions, making them ideal for long-term use. In particular, this is fantastic for patients who are having difficulty finding veins or require antibiotics via IV.
IV therapy using vein access devices reduces the pain associated with repeated needle insertions, improving patient comfort. By using these devices, fluids and medications can be administered more stably and reliably.
Using intravenous therapy, healthcare specialists can administer fluids, electrolytes, medications, and nutrients directly into the vein, resulting in immediate absorption into the bloodstream. In cases of acute dehydration or electrolyte imbalance, these machines are beneficial in hydration and transporting important materials.
IV Therapy And Vein Access Devices Market Trends
The IV therapy and vein access devices industry has experienced significant development due to technological advancements and the increasing prevalence of persistent illnesses. Advances in catheter design and substances that reduce infection risks have been key developments.
Real-time monitoring and precision drug delivery are provided by portable and clever infusion systems. With the rise of home healthcare services, there has been a rise in the demand for user-friendly devices that allow patients to manage their therapies outside of medical settings.
Infusion pumps with Wi-Fi and IoT integration offer improved information management and remote tracking, improving patient outcomes and healthcare performance. Personalized IV therapy solutions based on patient wishes and genetic profiles are also becoming more popular.
The advances not only improve the efficacy of treatments but also address the growing need for value-adding and minimally invasive treatments. IV therapy bypasses the stomach to deliver fluids, medications, and nutrients directly to the body. By using this technology, medical professionals can efficiently administer fluids to patients.
Rising Chronic Illness Creates Significant Opportunities in IV Therapy and Vein Access Devices
A growing aging population and an increase in chronic conditions will drive demand for these therapies and devices. Conditions such as diabetes, cancer, and cardiovascular illnesses provide a wide range of market opportunities for IV therapy and vein access devices.
Infusion pumps and catheter systems are becoming more popular due to the growing popularity of minimally invasive procedures. Increasing healthcare prices and improved healthcare infrastructure are both improving, which is logical since they both are improving.
The advancements in biotechnology and nanotechnology are leading to the development of next-generation vein access devices, which will likely revolutionize patient care in the future. Telehealth services are also providing opportunities for tracking and managing IV therapy remotely, enhancing accessibility for patients living far from or underserved areas.
Medical device companies and healthcare companies are also collaborating to develop tailored solutions to cope with specific medical needs, improving marketability.
Regulatory Process and Skilled Workers to Impede IV Therapy and Vein Access Devices
Developing regions with limited budgets may find it difficult to adopt superior devices and cures due to their high costs. A strict regulatory environment and long approval processes for new products may also prevent market expansion and delay the introduction of innovative solutions.
Furthermore, headaches caused by IV therapy, as well as catheter-associated bloodstream infections (CRBSIs), phlebitis, and thrombosis, are significant challenges.
A scarcity of trained employees also restricts the market in areas with a shortage of healthcare specialists. The availability and affordability of IV cures can also be affected by reimbursement issues and a wide range of coverage policies. Regulators, healthcare vendors, and tool manufacturers need to work together more to improve affordability, ensure safety, and streamline regulations to solve these problems.
Principal Consultant
A CAGR of 4.3% was reported between 2019 and 2023 for the IV therapy and vein access devices industry. In 2023, the IV therapy and vein access devices industry generated USD 27.3 billion, up from USD 21.9 billion in 2019.
A home IV remedy requires both proper training and education for patients and caregivers. To administer the therapy effectively and thoroughly, healthcare professionals provide instructions. Their role also involves monitoring the patient's development and providing ongoing support.
A vein access device like a central vein catheter, a peripheral vein catheter, or a peripherally inserted relevant catheter (PICC) can be used for home IV treatment in some cases. The devices provide a reliable route for administering fluids and medication, reducing the need for repeated needle insertions.
The procedure for administering home IVs must take place in a sterile, clean environment to minimize the risk of contamination. Following the prescribed treatment plan and observing proper hygiene practices are essential for patients and caregivers. In the event of contamination or complications, patients should notify the healthcare provider as soon as possible.
IV therapy administered at home can be a convenient alternative for patients requiring ordinary care. Patients can obtain treatment in a familiar and comfortable setting rather than having to make frequent clinic visits. The cost-effectiveness of home IV therapy may also be greater than total treatment in a sanatorium.
To perform domestic IV therapy, one must acquire the necessary equipment and components. Various materials, such as IV drips, tubing, needles, and other medical supplies are recommended with the help of healthcare professionals. Medical delivery stores or online stores carry these items, which can be purchased through their websites.
To administer IV remedies at home, a smooth and safe environment must be created. To achieve optimal results, the location must be well-lit, smooth, and free of distractions. It is imperative to adhere to proper hand hygiene practices and to sterilize the equipment.
For home IV therapy to be successful, the patient must be aware of the prison and regulatory requirements in the area. States or countries may also have their guidelines and rules regarding who can administer IV therapy.
Tier 1 companies account for 39.5% of the global market, establishing them as the leaders. Considering their global reach and substantial market share, tier 1 players are considered successful. Players offering a comprehensive product portfolio that covers a wide range of therapeutic areas fall into this category.
As part of their business plan, they provided high annual revenues, great brand recognition, and influence within the medical devices industry. Prominent companies within Tier 1 include Medtronic Inc., Pfizer Inc., and Fresenius SE & Co. KGaA.
Tier 2 players, with a market share of 27.6%, provide products and services in niche industries. A strong focus on research and development often accompanies their relationships with smaller healthcare providers. With a wide range of therapeutic areas covered, Tier 2 players offer a diverse product portfolio.
Tier 2 companies include CSL BD (Becton Dickinson & Company), Smith & Nephew Plc., Teleflex Medical Inc., and B. Braun Holding GmbH & Co. KG.
Tier 3 players focus on chronic diseases as a key factor driving demand for peripheral intravenous catheters. There is a smaller business existence and lower revenue, usually ranging from several hundred million to several billion dollars.
As far as Tier 3 players are concerned, their product portfolios tend to be more niche or specialized. Global reach is limited compared to companies at the top of the tier and at the bottom of the tier. Prominent players are Terumo Medical Corporation, Angiodynamics Inc., and Insulet Corporation.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The report provides an analysis of the IV therapy and vein access devices industries in different countries. India is expected to remain the top performer in Asia Pacific by 2034 with a CAGR of 8.6%. Meanwhile, Canada is predicted to exhibit a CAGR of 4.1% in the same period.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| United States | 2.4% |
| Canada | 4.1% |
| France | 3.9% |
| Germany | 2.4% |
| Italy | 3.5% |
| United Kingdom | 2.7% |
| China | 7.6% |
| India | 8.6% |
| South Korea | 6% |
Many factors influence the type of vein access device used in Canada, including age, reputation, vein condition, type of medicine, dose frequency, and length of treatment. Depending on these factors, the preferred type of device may also vary.
Concerning the drug administered, a peripheral IV catheter may also suffice as a short-term treatment option for young children and older children. However, patients with very active lifestyles and prone to VAD dislodgement might need unique infusion pumps or more secure access devices.
According to the Centers for Disease Control and Prevention, peripheral venous catheters should be changed every 72 to 96 hours to reduce the risk of phlebitis. Peripherally inserted significant catheters (PICCs) are another kind of VAD used in Canada.
PICCs are most generally inserted through the basilic, brachial, or cephalic veins. They are commonly used for patients who need IV access for a long period of time. In comparison to peripheral IVs, PICCs provide a more reliable and long-term access option.
Growth in the United Kingdom is expected to be significant in the coming years. The industry is forecast to expand at a 2.7% CAGR during the forecast period. All workplaces, including healthcare settings, are subject to HSE inspections and guidance on health and safety issues. Healthcare workers, who are exposed to the virus through their work activities, should be protected, according to the HSE.
A variety of vein entry devices are available in the United Kingdom, including peripheral cannulas, midlines, PICCs, and CVCs. In selecting these devices, considerations are made based on scientific indications, patient needs, and the duration of the treatment. In the NHS, antimicrobial dressings and aseptic techniques are being used to lower the rate of catheter-related bloodstream infections (CRBSIs).
Devices for vein access are approved and monitored by regulatory agencies such as the Medicines and Healthcare Products Regulatory Agency (MHRA). Several innovations are being implemented to enhance patient safety, including antimicrobial-lined catheters and needle-free connectors.
The use of ultrasound-guided insertion techniques is also extensively practiced to increase the reliability of the procedure and to minimize headaches. In the United Kingdom, patients receiving long-term IV therapy are also taught how to take care of their machines to prevent infections and other problems.
IV therapy and vein access devices in India have experienced positive growth. India's market is expected to expand at a CAGR of 8.6% between 2024 and 2034. With a huge and diverse population, IV therapy and access to veins are crucial to India's healthcare transportation system.
From well-equipped hospitals to renowned health facilities, IV therapy is widely used throughout cities and rural settings. With a variety of admission options and high-quality care, India's healthcare system encompasses both the public and private sectors.
A variety of factors affect the choice of these devices, including the availability of trained healthcare personnel, the type of treatment needed, and the economic situation. Urban areas may have more access to advanced gadgets and technologies, whereas rural areas may rely on simpler methods due to a lack of resources.
In India, IV therapy and vein access devices face challenging circumstances such as a high patient load, a fluctuating high quality of care, and limited resources. Despite these challenging circumstances, numerous advancements have been made to improve patient outcomes, including the adoption of global standards and protocols.
To reduce complications such as infections and thrombosis associated with vein access devices, initiatives are underway to improve healthcare infrastructure.
CDSCO, which oversees regulatory compliance with protection requirements, provides regulatory oversight of vein access gadgets. The government is also conducting public health campaigns and educational programs to educate the public on the proper use and maintenance of these devices, which is crucial in a country with so many healthcare issues.
The following section provides information about the leading segments in the industry. A 32.5% share of the value share was accounted for by IV therapy and vein access intravenous catheters. Based on the application, medication administration accounted for 31.5% of the market share in 2023.
| Type | IV Therapy and Vein Access Intravenous Catheters |
|---|---|
| Value Share (2023) | 32.5% |
IV therapy and vein access intravenous catheters contributed approximately 32.5% to industry revenue in 2023. Patients and physicians alike prefer intravenous catheters for their user-friendly material composition compared to their alternative counterparts.
As drugs enter the bloodstream at once, they are quickly absorbed and may start to act almost immediately. In emergencies involving time limitations, such as coronary heart attacks and excessive hypersensitivity reactions, this practice is beneficial.
The dosage and rate of treatment can be controlled precisely, ensuring that the patient receives the precise amount of drug or fluid needed. In chemotherapy or in intensive care settings, this is crucial in conditions that require tight therapeutic manipulation. Patients receiving treatment with PICCs or midline catheters can continue to perform their normal activities.
Patients who undergo long-term therapy may benefit from this because it improves their quality of life. Ultrasound-guided insertion techniques and antimicrobial coatings are included in modern vein access devices. Infections, thrombosis, and other IV therapy complications can be reduced by using these innovations.
| Application | Medication Administration |
|---|---|
| Value Share (2023) | 31.5% |
IV therapy has a number of significant advantages, including a rapid onset of motion. Medicines administered intravenously enter the bloodstream without delay, which results in faster healing effects than those administered orally or by other means.
The importance of immediate action lies in emergency medication, intensive care, and conditions that require rapid intervention, such as infections, acute pain, or cardiac emergencies. IV administration allows for direct delivery of the entire dose into the bloodstream without having to pass through the gastrointestinal tract or the liver for first-pass metabolism.
Thus, antibiotics, chemotherapeutics, and positive cardiac therapies benefit from greater bioavailability and predictable pharmacokinetics when administered via IV.
IV therapy enables the continuous delivery of medicinal drugs, which is crucial to maintaining a high drug level inside the body. The need for constant plasma concentrations is especially important for drugs like insulin, heparin, and vasopressors with narrow therapeutic windows.
With IV pumps and other IV transport systems, you can manage infusion rates accurately and ensure top-notch therapeutic results. In modern medicine, many complex molecules cannot be taken orally, including monoclonal antibodies, biologics, and antibiotics.
To ensure that these therapies are administered effectively, IV delivery is often required. The demand for reliable vein access devices is growing as these advanced therapies are developed.
Leading organizations are heavily investing in research and development to innovate new merchandise and improve present ones. Innovations consisting of antimicrobial-covered catheters, needleless connectors, and ultrasound-guided insertion strategies are enhancing patient safety and procedural success.
Developing tailor-made solutions is easier when businesses work with hospitals, clinics, and healthcare systems. As a result of these partnerships, joint development initiatives and clinical trials are often conducted.
Recent Industry Developments in the IV Therapy and Vein Access Devices
In terms of type, the industry is divided into Therapy and Vein Access Implantable Ports, Therapy and Vein Access Intravenous Catheters, Hypodermic IV Therapy and Vein Access Needles, Therapy and Vein Access Infusion Pumps, Other IV Therapy and Vein Access Devices Therapy and Vein Access Implantable Ports is further classified into Single Lumen Implantable Port, Double Lumen Implantable Port.
Therapy and Vein Access Intravenous Catheters is further classified into Peripheral Intravenous Catheter, Central Intravenous Catheter, Peripherally Inserted Central Catheter.
In terms of application, the industry is segregated into Volume Expanders, Medication Administration, Blood-Based Products, Nutrition & Buffer Solutions.
In terms of end use, the industry is segmented into Hospitals, Ambulatory Surgical Centres, and Clinics.
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia, East Asia, the Middle East, and Africa have been covered in the report.
A CAGR of 5.1% is projected between 2024 and 2034 in the IV therapy and vein access devices sector.
The IV therapy and vein access devices market was valued at USD 21.9 billion in 2023.
It is expected that the IV therapy and vein access devices industry will reach USD 47.3 billion by 2034.
India is expected to expand at an 8.6% CAGR during the assessment period.
The key players in the IV therapy and vein access devices industry include BD (Becton Dickinson & Company), B. Braun Holding GmbH & Co. KG, Terumo Medical Corporation, and Teleflex Medical Inc.
1. Executive Summary
2. Industry Introduction, including Taxonomy and Market Definition
3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections
5. Pricing Analysis
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034
6.1. Type
6.2. Medical Application
6.3. End User
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Type
7.1. IV Therapy and Vein Access Implantable Ports
7.1.1. Single Lumen Implantable Port
7.1.2. Double Lumen Implantable Port
7.2. IV Therapy and Vein Access Intravenous Catheters
7.2.1. Peripheral Intravenous Catheter
7.2.2. Central Intravenous Catheter
7.2.3. Peripherally Inserted Central Catheter
7.3. Hypodermic IV Therapy and Vein Access Needles
7.4. IV Therapy and Vein Access Infusion Pumps
7.5. Other
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Medical Application
8.1. Volume Expanders
8.2. Medication Administration
8.3. Blood-Based Products
8.4. Nutrition & Buffer Solutions
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User
9.1. Hospitals
9.2. Ambulatory Surgical Centres
9.3. Clinics
10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
10.1. North America
10.2. Latin America
10.3. Western Europe
10.4. South Asia
10.5. East Asia
10.6. Eastern Europe
10.7. Middle East & Africa
11. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
12. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
14. South Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
15. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
16. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
17. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
18. Sales Forecast 2024 to 2034 by Type, Medical Application, and End User for 30 Countries
19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
20. Company Profile
20.1. BD (Becton Dickinson & Company)
20.2. B. Braun Holding GmbH & Co. KG
20.3. Terumo Medical Corporation
20.4. Teleflex Medical Inc.
20.5. Medtronic Inc.
20.6. Smith & Nephew Plc.
20.7. Angiodynamics Inc.
20.8. Pfizer Inc.
20.9. Insulet Corporation
20.10. Fresenius SE & Co. KGaA
Explore Healthcare Insights
View Reports
IV Therapy and Vein Access Devices Market
